Table 1 Clinical, immune-hematological, anthropometric, body composition, and histopathological data of the studied cohorts; all cancer patients (ACP, n = 50) divided into 3 groups: normal weight, NW (BMI = 18.5–24.9) n = 26; overweight, OW (BMI = 25-29.9) n = 11; obese, OB (BMI = 30–39.9) n = 13, with the statistical significance of the clinical and immune-hematological values

From: Use of membrane lipidome, body weight, and composition in stratification of early breast cancer patients

 

ACP

NW

OW

OB

Clinical and Immuno-hematological status§

Mean ± sd

Mean ± sd

Mean ± sd

Mean ± sd

Menarche (age)

12.49 ± 1.44

12.67 ± 1.40

12.17 ± 1.46

12.00 ± 1.53

Pregnacies (n°)

1.27 ± 0.95

1.08 ± 1.00

1.40 ± 1.02

1.36 ± 0.77

Systolic pressure (mmHg)

120 ± 7.07

117.54 ± 12.97

123.64 ± 16.25

124.50 ± 8.20

Diastolic pressure (mmHg)

74.17 ± 14.14

72.92 ± 8.65

77.45 ± 9.53

74.00 ± 6.24

Glycemia (mg/dL)

93.4 ± 12.48

85.58 ± 9.76

93.91 ± 7.65a

104.25 ± 14.57b,d

Cholesterol (mg/dL)

187.34 ± 30.52

185.96 ± 32

199.27 ± 28.56

179.83 ± 26.90

Triglycerides (mg/dL)

95.4 ± 45.12

80.73 ± 29.57

110.91 ± 56.72a

116.83 ± 48.12c

Lymphocytes (mil/mm3)

2.00 ± 0.54

1.97 ± 0.43

1.80 ± 0.32

2.33 ± 0.72d

Neutrophils (mil/mm3)

4.40 ± 1.56

4.36 ± 1.27

4.09 ± 1.70

4.90 ± 1.83

 

n (%)

n (%)

n (%)

n (%)

 Familiarity

20 (40)

14 (54)

3 (27)

3 (23)

 Menopause

22 (44)

8 (30)

6 (54)

8 (62)

 Smoke

11 (22)

5 (19)

3 (27)

2 (15)

 Comorbidities

20 (40)

9 (33)

3 (27)

9 (69)

Anthropometric and body composition measures

Mean ± sd

Mean ± sd

Mean ± sd

Mean ± sd

 Weight (kg)

72.2 ± 18.64

59.75 ± 6.10

73.37 ± 5.91

99.18 ± 14.57

 Height (m)

1.63 ± 0.06

1.63 ± 0.05

1.61 ± 0.05

1.66 ± 0.08

 Body Mass Index

27.23 ± 6.39

22.49 ± 1.95

28.43 ± 1.43

36.09 ± 4.97

 Waist circumference (cm)

88.03 ± 15.63

77.00 ± 7.15

91.55 ± 5.51

107.73 ± 13.58

 Hip circumference (cm)

104.26 ± 11.66

96.44 ± 4.88

104.68 ± 4.28

120.19 ± 9.47

 WHR

0.84 ± 0.08

0.80 ± 0.06

0.88 ± 0.06

0.91 ± 0.08

 Resistance at 50 kHz– (Ohm)

512.16 ± 79.40

548.85 ± 78.36

480.91 ± 55.62

461.85 ± 60.34

 Reactance at 50 kHz (Ohm)

45.02 ± 7.14

46.78 ± 8.07

44.05 ± 5.15

42.28 ± 5.76

 Phase angle (°)

5.08 ± 0.62

4.90 ± 0.67

5.31 ± 0.53

5.27 ± 0.49

 Fat mass (kg)

 Fat mass (%)

26.01 ± 14.09

33.53 ± 9.58

16.03 ± 5.07

26.31 ± 6.22

27.59 ± 3.21

37.27 ± 2.43

45.36 ± 11.72

45.17 ± 4.93

 Fat free mass (kg)

 Fat free mass (%)

46.71 ± 5.56

66.47 ± 9.58

43.68 ± 2.59

73.70 ± 6.22

47.97 ± 3.58

62.73 ± 2.43

53.82 ± 5.05

54.83 ± 4.93

 Total body water L

 Total body water %

36.53 ± 6.09

52.05 ± 8.34

33.16 ± 4.36

56.62 ± 7.73

37.18 ± 4.55

50.80 ± 5.88

42.96 ± 5.00

43.55 ± 2.57

Histopathological status

n (%)

n (%)

n (%)

n (%)

 Grade G1

6 (12)

3 (12)

2 (18)

1 (8)

 Grade G2

20 (40)

9 (35)

5 (46)

6 (46)

 Grade G3

15 (30)

10 (38)

2 (18)

2 (15)

 Grade N.A

9 (18)

4 (15)

2 (18)

4 (31)

 Estrogen receptor positive (ER (10%)

37 (74)

21 (81)

7 (64)

9 (69)

 Estrogen receptor negative (ER−)

4 (8)

1 (4)

3 (27)

0 (0)

 Estrogen receptor (ER) N.A– n (%)

9 (18)

4 (15)

1 (9)

4 (31)

 Progesterone receptor positive (PR+) (10%)

34 (68)

19 (73)

7 (64)

8 (61)

 Progesterone receptor negative (PR−)

7 (14)

3 (12)

3 (27)

1 (8)

 Progesterone receptor (PR) N.A− n (%)

9 (18)

4 (15)

1 (9)

4 (31)

 Human epidermal growth factor receptor 2 positive (HER2+)

2 (4)

1 (4)

1 (9)

0 (0)

 Human epidermal growth factor receptor 2 negative (HER2−)

38 (76)

21 (81)

8 (72)

9 (69)

 Human epidermal growth factor receptor 2 (HER2) N.A. n (%)

10 (20)

4 (15)

2 (18)

4 (31)

 High Ki-67 (H-Ki-67)

21 (42)

12 (46)

4 (36)

5 (38.5)

 Low Ki-67 (L-Ki-67)

19 (38)

10 (39)

4 (36)

5 (38.5)

 N.A. Ki-67

10 (20)

4 (15)

3 (27)

3 (23)

 Luminal A (ER+/PR+/HER2−/L-Ki-67)

18 (36)

10 (38)

2 (18)

5 (38)

 Luminal B (ER+/PR+/HER2−/H-Ki-67)

17 (34)

10 (38)

2 (18)

4 (31)

 Luminal B (ER+/PR+/HER2+/H-Ki-67)

0 (0)

0 (0)

0 (0)

0 (0)

 HER2+ (ER−; PR−; HER2+)

3 (6)

1 (4)

2 (18)

0 (0)

 Triple negative (ER−/PR−/HER2−)

2 (4)

1 (4)

1 (9)

0 (0)

 N.A – n (%)

10 (20)

4 (15)

4 (36)

4 (31)

  1. §Significance (unpaired t-test). aOW vs NW p ≤ 0.0398. bOB vs NW p ˂ 0.0001. cOB vs NW p = 0.0062. dOB vs OW p ≤ 0.046.
  2. Estrogen Receptor positive (ER+) ≥10% positive staining for ER; Estrogen Receptor negative (ER−) <10% positive staining for ER; Progesterone Receptor positive (PR+) ≥10% positive staining for PR, Progesterone Receptor negative (PR−) <10% positive staining for PR, HER2 positive: IHC (immunohistochemistry) score 3+ or Her2 gene amplification, HER2 negative: IHC score 0-1 or score 2 with no Her2 gene amplification.
Back to article page